HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Isolated Brain Metastases as the First Relapse After the Curative Surgical Resection in Non-Small-Cell Lung Cancer Patients With an EGFR Mutation.

AbstractINTRODUCTION:
The aim of this study was to clarify the incidence and disease behavior of brain metastases (BM) without extracranial disease (ie, isolated BM) as the first relapse after curative surgery in non-small-cell lung cancer (NSCLC) patients, analyzed according to epidermal growth factor receptor (EGFR) mutation status.
PATIENTS AND METHODS:
A review of the medical charts of consecutive NSCLC patients diagnosed between 2005 and 2016 with BM as the first relapse after curative surgery was performed.
RESULTS:
Among 1191 patients evaluated for EGFR mutation status, 28 patients who met the inclusion criteria were divided into 2 groups: EGFR mutation group (16 patients) and wild type group (12 patients). At BM diagnosis, the EGFR-mutation group tended to have more commonly isolated BM compared with that in the wild type group (11 of 16 vs. 3 of 12; P = .054). In the EGFR mutation group, the patients with isolated BM showed longer overall survival than those with non-isolated BM (39.6 vs. 18.7 months; P = .038). Notably, isolated BM in the EGFR mutation group was neurologically asymptomatic in 10 of the 11 patients. With regard to upfront treatment for isolated BM in the EGFR mutation group, 10 of 11 patients were treated with only cranial radiotherapy without EGFR tyrosine kinase inhibitors, but two-thirds of the patients (7 of 11; 64%) developed extracranial disease during the study period.
CONCLUSION:
In curatively resected NSCLC patients with EGFR mutation, isolated BM would be correlated with better prognosis, but regarded as a precursor to systemic disease. Because isolated BM can be neurologically asymptomatic, it would be important to periodically perform cranial evaluation to detect isolated BM.
AuthorsShinko Sadoyama, Akimasa Sekine, Hiroaki Satoh, Tae Iwasawa, Terufumi Kato, Satoshi Ikeda, Masafumi Sata, Tomohisa Baba, Erina Tabata, Yuko Minami, Kenji Nemoto, Kenji Hayashihara, Takefumi Saito, Koji Okudela, Kenichi Ohashi, Michihiko Tajiri, Takashi Ogura
JournalClinical lung cancer (Clin Lung Cancer) Vol. 19 Issue 1 Pg. e29-e36 (01 2018) ISSN: 1938-0690 [Electronic] United States
PMID28669848 (Publication Type: Journal Article)
CopyrightCopyright © 2017 Elsevier Inc. All rights reserved.
Chemical References
  • EGFR protein, human
  • ErbB Receptors
Topics
  • Aged
  • Brain Neoplasms (mortality, secondary, surgery)
  • Carcinoma, Non-Small-Cell Lung (mortality, secondary, surgery)
  • Cells, Cultured
  • ErbB Receptors (genetics)
  • Female
  • Humans
  • Lung Neoplasms (mortality, pathology, surgery)
  • Male
  • Mutation (genetics)
  • Neoplasm Metastasis
  • Neoplasm Staging
  • Pneumonectomy
  • Survival Analysis

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: